Mr Ronnie Crawford, LCSW | |
269 County Road 6100, Baldwyn, MS 38824-8516 | |
(662) 365-5153 | |
Not Available |
Full Name | Mr Ronnie Crawford |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 269 County Road 6100, Baldwyn, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346455060 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | CO471 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Ronnie Crawford, LCSW 269 County Road 6100, Baldwyn, MS 38824-8516 Ph: (662) 365-5153 | Mr Ronnie Crawford, LCSW 269 County Road 6100, Baldwyn, MS 38824-8516 Ph: (662) 365-5153 |
News Archive
According to a Johns Hopkins Medicine study published today in JAMA Pediatrics, exposure to police — even in instances in which the officers are providing assistance — may be detrimental to the health and well-being of Black youth, especially males, and can be associated with poor mental health, substance use, risky sexual behaviors and impaired safety.
bioMD Limited (ASX:BOD), a company with assets in regenerative tissue engineering technologies today announced the appointment of a new Chairman, a new MD and other changes to its Board. This follows shareholder approval for the acquisition of Allied Medical Ltd., a company that specialises in the sales, distribution and commercialisation of medical technologies.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.
TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.
› Verified 5 days ago